Group 1: Financial Performance - In 2024, the company achieved a revenue of 721 million CNY and a net profit of 108 million CNY, with a first-quarter revenue of 185 million CNY and a net profit of 31.55 million CNY in 2025 [3][10] - R&D investment for 2024 was 158 million CNY, accounting for 21.96% of total revenue [10] Group 2: Product Development and Market Potential - The innovative drug CKBA for vitiligo has completed 100% of subject enrollment in Phase II clinical trials, with results expected in July 2025, indicating significant market potential [2][11] - The company aims to develop 1-2 major indications for CKBA within the next 3-5 years [11] - The "He Wei Zheng Chang Wan" product registration is under review, with production capacity ready to meet domestic demand once approved [3][4] Group 3: Strategic Growth Areas - The company plans to expand its gastrointestinal drug segment, targeting over 1 billion CNY in sales within 3-5 years [4][11] - In the sexual health sector, the company is enhancing its product lineup, including the clinical trial of lidocaine and procaine aerosol, with a goal to strengthen market competitiveness [5][8] - The ophthalmic product "Woli Ting" is expected to grow significantly, with the potential to become the first drug for presbyopia treatment in China [5][7] Group 4: Cost Management and Operational Efficiency - Sales expenses increased by 14.15% and management expenses by 12.64%, but the company plans to optimize its cost structure while maintaining R&D and brand promotion investments [6][10] - The company is focusing on budget management and strict control of expenditures to enhance profitability [6] Group 5: Market Challenges and Responses - The sexual health drug segment faced a revenue decline of 20.87%, prompting the company to increase brand promotion and patient education efforts [8][9] - The company is addressing the impact of healthcare policy changes on product sales, with a strategy to enrich its product portfolio and increase revenue sources [8]

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于 2024年 3月 27日召 开第五届董事会第二次会议和第五届监事会第二次会议，于 2024年 4月 12日召 开了 2024 年第二次临时股东大会，审议通过了《关于<广东泰恩康医药股份有 限公司 2024 年员工持股计划（草案）>及其摘要的议案》等相关议案，同意公 司实施 2024 年员工持股计划（以下简称"本员工持股计划"）并授权董事会办 理相关事宜。2024 年 5 月 6 日，公司完成本员工持股计划股票购买。具体情况 详见公司分别于 2024 年 3 月 28 日、2024 年 4 月 12 日、2024 年 5 月 7 日披露于 巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 鉴于本员工持股计划的锁定期已于 2025 年 5 月 6 日届满， 根据《关于上市 公司实施员工持股计划试点的指导意见》及《深圳证券交易所上市公司自律监 管指引第 2 号—创业板上市公司规范运作》的相关要求，现将公司本员工持股 计划的相关情况公告如下： 一、 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-032 广东泰恩康医药股份有限公司 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日 在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《泰恩康 2024 年年度报告》。 为便于广大投资者进一步了解公司 2024 年年度经营情况，公司定于 2025 年 5 月 12 日（星期一）15:00 至 16:00 时在"约调研"小程序举行 2024 年度网上业 绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者可登陆"约 调研"小程序参与互动交流。为广泛听取投资者的意见和建议，提前向投资者征 集问题，提问通道自发出公告之日起开放，公司将在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 参与方式一：在微信小程序中搜索"约调研"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"约调研"小程序，即可参与交流。 出席本次网上说明会的人 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [8][29]. Core Insights - The industry is experiencing a return to normal growth, with a notable performance in chemical pharmaceuticals, while the overall revenue growth for 2024 is projected to decline by 0.6% year-on-year, marking the first decline in recent years [12][14]. - The report highlights a significant disparity among sectors, with chemical pharmaceuticals showing a remarkable net profit growth of 97.7%, while biological products face substantial short-term performance pressure [17][18]. - The current low allocation and valuation levels present a high cost-performance ratio for investments in the pharmaceutical sector, suggesting it is an excellent time to allocate resources [19][28]. Summary by Sections 1. Innovation in the Pharmaceutical Chain - The report notes that the impact of national procurement and anti-corruption measures is gradually diminishing, leading to a normal release of rigid demand in hospitals [11]. - The overall revenue growth for the industry in 2024 is projected at -0.6%, with net profit and non-recurring net profit declining by 8.1% and 5.9% respectively [12][13]. 2. Investment Recommendations - The report suggests focusing on the innovation drug supply chain (Biotech + CXO + upstream) and certain overseas medical devices, recommending companies such as Aosaikang, Yifang Bio, and WuXi AppTec for investment [29]. - For in-hospital products (traditional Chinese medicine, chemical pharmaceuticals, and medical devices), companies like Hengrui Medicine and Mindray Medical are highlighted as having more certain growth prospects [29]. 3. Market Positioning - The report indicates that the allocation of public fund products in pharmaceutical stocks has decreased from 11.2% in Q1 2024 to 8.7% in Q4 2024, with a slight recovery to 9.1% by Q1 2025 [19][21]. - The pharmaceutical sector's price-to-earnings ratio is at a 10-year low, suggesting potential for growth as innovative products continue to emerge [22][24].

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

证券代码：301263 证券简称：泰恩康 公告编号：2025-030 广东泰恩康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司广东泰恩 康制药厂有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的利丙双卡因乳膏境内生产药品注册上市许可申请《受理通知书》，国家 药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品的 药品注册上市许可申请进行了审查，决定予以受理。现将相关情况公告如下： 一、申请注册药品的基本情况 受理号：CYHS2501621 药品名称：利丙双卡因乳膏 二、药品相关情况简介 利丙双卡因乳膏是一种外用局部麻醉镇痛制剂，适用于各类针穿刺和皮肤、 黏膜浅层的外科手术麻醉。随着生活水平的提高和医疗技术的发展，市场对于 局部麻醉药物的需求不断增加。利丙双卡因乳膏凭借其便利、安全性高和无依 赖性等优点，逐渐成为临床浅表层麻醉用药的新趋势，广泛适用于整形美容科、 普外科、麻醉科、泌尿科、皮肤病科等。 三、同类药品 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The domestic production of "Hewei Zhengchang Wan" is imminent, and the clinical progress of the innovative drug for vitiligo is steady [5] - The company reported a revenue of 721 million yuan for 2024, a decrease of 5.23% year-on-year, and a net profit of 108 million yuan, down 32.45% year-on-year [7] - The company expects significant improvement in profitability following the domestic launch of gastrointestinal medications [7] Financial Performance Summary - Revenue projections for the company are as follows: 2023: 761 million yuan, 2024: 721 million yuan, 2025E: 902 million yuan, 2026E: 1,083 million yuan, 2027E: 1,296 million yuan [6] - The expected growth rates for revenue are -2.90% in 2023, -5.23% in 2024, 25.15% in 2025, 20.06% in 2026, and 19.60% in 2027 [6] - The projected net profit for 2025 is 176 million yuan, with a year-on-year growth of 62.37% [6] - The earnings per share (EPS) are forecasted to be 0.41 yuan in 2025, 0.56 yuan in 2026, and 0.71 yuan in 2027 [6] Business Segmentation - In 2024, the revenue breakdown is as follows: gastrointestinal medications: 206 million yuan (up 1.04% year-on-year), ophthalmic medications: 185 million yuan (up 0.13%), sexual health: 178 million yuan (down 20.87%), traditional Chinese medicine and external medications: 95 million yuan (down 10.03%) [7] - The company has made progress in its R&D pipeline, with the II phase clinical trial for CKBA ointment for vitiligo fully enrolled [7] - The company has received acceptance for the domestic listing application of "Hewei Zhengchang Wan" and is progressing with other innovative drugs [7]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 22.77 CNY based on a 69 times price-to-earnings ratio for 2025 [2][5]. Core Views - The company's performance is under short-term pressure but is expected to grow in the medium to long term. The revenue forecast for 2025-2027 has been adjusted, with earnings per share projected at 0.33, 0.61, and 1.01 CNY respectively [1][2]. - The company reported a revenue of 721 million CNY for 2024, a decrease of 5.2% year-on-year, and a net profit of 108 million CNY, down 32.4% year-on-year. The first quarter of 2025 saw a revenue of 185 million CNY, a decline of 2.35% [9]. - The company is facing increased competition in the two-sex health sector, leading to a 20.87% decline in revenue from this segment. However, there is significant growth potential in the gastrointestinal medication market, with new product registrations expected to boost revenue [9]. Financial Summary - The company's financial performance shows a projected revenue increase from 721 million CNY in 2024 to 1.52 billion CNY in 2027, reflecting a compound annual growth rate of 31.9% [4][11]. - The gross margin is expected to improve from 56.7% in 2024 to 71.7% in 2027, while the net profit margin is projected to rise from 15.0% to 28.2% over the same period [4][11]. - The company's earnings per share are forecasted to increase from 0.25 CNY in 2024 to 1.01 CNY in 2027, indicating strong growth potential [4][11].

Core Viewpoint - The company is facing significant pressure on its performance due to rising costs and declining revenues in certain segments, particularly in the two-sex health medication category, while showing potential growth in gastrointestinal medications [1][2]. Financial Performance - In 2024, the company achieved revenue of 721 million yuan, a year-on-year decrease of 5.23%, with a net profit attributable to shareholders of 108 million yuan, down 32.45% year-on-year [1]. - For Q1 2025, the company reported revenue of 185 million yuan, a decline of 2.35%, and a net profit of 32 million yuan, down 30.62% year-on-year [1]. - The decline in profits is attributed to rapid growth in expenses, including management expenses of 75 million yuan (up 12.64% year-on-year) and R&D expenses of 86 million yuan (up 37.42% year-on-year) in 2024 [1]. Segment Performance - Revenue from two-sex health medications fell to 178 million yuan, a decrease of 20.87%, primarily due to intensified market competition [2]. - Revenue from gastrointestinal medications remained stable at 206 million yuan, with a slight increase of 1.04% year-on-year [1][2]. - The company is optimistic about the potential of its gastrointestinal medication, Hewei Zhengchang Wan, which has received acceptance for its production registration application and is expected to be approved within the year [2]. R&D Progress - The company has made significant progress in R&D, with several key developments: - The CKBA ointment for vitiligo has completed Phase II enrollment, with data expected in mid-2025 [2]. - The NDA for compound sodium sulfate tablets was accepted in November 2024, marking the first application in the country, with approval anticipated within the year [2]. - The company is also advancing in ophthalmic medications, with the sodium dichloride eye drops expected to be approved this year [2]. - In the two-sex health segment, the lidocaine and prilocaine aerosol has completed its first enrollment and is expected to submit an NDA within the year [2]. Earnings Forecast - Based on the 2024 annual report, the company has revised its revenue forecasts, projecting earnings per share of 0.33, 0.61, and 1.01 yuan for 2025-2027, respectively [3]. - The target price for the company is set at 22.77 yuan, based on a 69 times price-to-earnings ratio for 2025 [3].